Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01264679 · ClinicalTrials.gov registry record · Phase 3
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT01264679 is a Phase 3 study that was terminated before completion, run by AMAG Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT01264679, a Phase 3 study, was terminated before completion, sponsored by AMAG Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
Study AMAG-FER-CKD-253 is an extension study of the combined AMAG-FER-CKD-251 (NCT01155375) and AMAG-FER-CKD-252 (NCT01155388) studies to evaluate the efficacy and safety of episodic treatment of iron deficiency anemia (IDA) with ferumoxytol.
Interventions
- DRUG Ferumoxytol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-12-27 |
| Est. Completion | 2015-04-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01264679
The ClinicalTrials.gov registry entry for NCT01264679 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ferumoxytol is the first listed.
NCT01264679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01264679 about?
NCT01264679 is a clinical study titled "A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease". Study AMAG-FER-CKD-253 is an extension study of the combined AMAG-FER-CKD-251 (NCT01155375) and AMAG-FER-CKD-252 (NCT01155388) studies to evaluate the efficacy and safety of episodic treatment of iron deficiency anemia (IDA) with ferumoxytol.
What is the current status of trial NCT01264679?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2011-12-27. Estimated completion is 2015-04-24.
What interventions are being tested in trial NCT01264679?
The interventions under investigation include: Ferumoxytol (DRUG).
Who is sponsoring clinical trial NCT01264679?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.